Código 293890 (Harmonized System 2012 by 6 digits)
2023: US$56.9M, Total Trade Exchange
2023: US$4.55M, International Sales
2023: US$52.3M, International Purchases
In 2023, the trade exchange (includes international purchases and sales) of Glycosides, Natural or Reproduced by Synthesis; their Salts, Ethers, Esters and other Derivatives (Exc. Rutoside "Routine" and its Derivatives) was US$56.9M.
In 2023, the states with the most international sales in Glycosides, Natural or Reproduced by Synthesis; their Salts, Ethers, Esters and other Derivatives (Exc. Rutoside "Routine" and its Derivatives) were Ciudad de México (US$1.83M) and Estado de México (US$353k).
The states with the most international purchases in 2023 were Ciudad de México (US$19.4M), Estado de México (US$15.9M), Jalisco (US$6.19M), Nuevo León (US$5.32M), and Querétaro (US$2.71M).
In 2023, the main commercial destinations of Glycosides, Natural or Reproduced by Synthesis; their Salts, Ethers, Esters and other Derivatives (Exc. Rutoside "Routine" and its Derivatives) were Costa Rica (US$842k), United States (US$715k), Brazil (US$285k), France (US$170k), and Chile (US$86.4k).
The main commercial origins of Glycosides, Natural or Reproduced by Synthesis; their Salts, Ethers, Esters and other Derivatives (Exc. Rutoside "Routine" and its Derivatives) in 2023 were China (US$14.5M), Spain (US$12.6M), France (US$9.72M), Malaysia (US$6.48M), and South Korea (US$4.2M).
In the global context, the main exporting countries of Glycosides, Natural or Reproduced by Synthesis; their Salts, Ethers, Esters and other Derivatives (Exc. Rutoside "Routine" and its Derivatives) in 2022 were China (US$974M), France (US$161M), and Malaysia (US$86.9M). In the same year, the main importing countries of Glycosides, Natural or Reproduced by Synthesis; their Salts, Ethers, Esters and other Derivatives (Exc. Rutoside "Routine" and its Derivatives) were United States (US$418M), Hong Kong (US$158M), and India (US$122M).
US$56.9M, Total Trade Exchange (2023)
In 2023, the total trade exchange of Glycosides, Natural or Reproduced by Synthesis; their Salts, Ethers, Esters and other Derivatives (Exc. Rutoside "Routine" and its Derivatives) in Mexico (including international purchases and sales) was US$56.9M.
The visualizations show the net balance of Glycosides, Natural or Reproduced by Synthesis; their Salts, Ethers, Esters and other Derivatives (Exc. Rutoside "Routine" and its Derivatives) at the level of states and countries. Colors more similar to blue, indicate that the territory presented a higher level of international sales. Colors more similar to red, indicate that the territory presented a higher level of international purchases.
July, 2024
In July 2024, international sales of Glycosides, Natural or Reproduced by Synthesis; their Salts, Ethers, Esters and other Derivatives (Exc. Rutoside "Routine" and its Derivatives) were US$284k, while international purchases reached US$5.72M. The above results in a trade balance of -US$5.44M.
2024-Q3: US$282k, International Sales
The visualization shows the quarterly concentration of international sales of Glycosides, Natural or Reproduced by Synthesis; their Salts, Ethers, Esters and other Derivatives (Exc. Rutoside "Routine" and its Derivatives) at state level.
In the third quarter of 2024, international sales were US$282k, being the states with the most sales Estado de México (US$209k) and Ciudad de México (US$72.5k).
Ciudad de México: US$1.83M, State with the Most International Sales (2023)
Costa Rica: US$842k, Main commercial destination (2023)
In 2023, the states with the highest international sales in Glycosides, Natural or Reproduced by Synthesis; their Salts, Ethers, Esters and other Derivatives (Exc. Rutoside "Routine" and its Derivatives) were Ciudad de México (US$1.83M) and Estado de México (US$353k).
In 2023, the countries with the most international purchases from Mexico were Costa Rica (US$842k), United States (US$715k), Brazil (US$285k), France (US$170k), and Chile (US$86.4k).
Ciudad de México: US$19.4M, State with the Most International Purchases (2023)
China: US$14.5M, Main Commercial Origin (2023)
In 2023, the states with the highest international in Glycosides, Natural or Reproduced by Synthesis; their Salts, Ethers, Esters and other Derivatives (Exc. Rutoside "Routine" and its Derivatives) were Ciudad de México (US$19.4M), Estado de México (US$15.9M), Jalisco (US$6.19M), Nuevo León (US$5.32M), and Querétaro (US$2.71M).
The countries with the most international sales to Mexico in 2023 were China (US$14.5M), Spain (US$12.6M), France (US$9.72M), Malaysia (US$6.48M), and South Korea (US$4.2M).
The RCA-Complexity diagram compares the Revelead Comparative Advantages of states in Glycosides, Natural or Reproduced by Synthesis; their Salts, Ethers, Esters and other Derivatives (Exc. Rutoside "Routine" and its Derivatives) and the Economic Complexity Index of each state.
RCA values greater than 1 indicate that the state has comparative advantages in Glycosides, Natural or Reproduced by Synthesis; their Salts, Ethers, Esters and other Derivatives (Exc. Rutoside "Routine" and its Derivatives). On the other hand, high levels of complexity (ECI) are associated with higher levels of income, potential for economic growth, lower income inequality and lower emissions.
The visualizations show the global market for Glycosides, Natural or Reproduced by Synthesis; their Salts, Ethers, Esters and other Derivatives (Exc. Rutoside "Routine" and its Derivatives). In both charts, Mexico stands out in order to identify its participation in the export and import market.
In 2022, the main exporting countries of Glycosides, Natural or Reproduced by Synthesis; their Salts, Ethers, Esters and other Derivatives (Exc. Rutoside "Routine" and its Derivatives) were China (US$974M), France (US$161M), and Malaysia (US$86.9M). In the same year, the main importing countries for Glycosides, Natural or Reproduced by Synthesis; their Salts, Ethers, Esters and other Derivatives (Exc. Rutoside "Routine" and its Derivatives) were United States (US$418M), Hong Kong (US$158M), and India (US$122M).